Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.5.2003

Association of Reduced Immunohistochemical Expression of E-cadherin with a Poor Ovarian Cancer Prognosis - Results of a Meta-analysis  

Peng, Hong-Ling (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University)
He, Lei (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University)
Zhao, Xia (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.5, 2012 , pp. 2003-2007 More about this Journal
Abstract
Purpose: E-cadherin is a transmemberane protein which is responsible for adhesion of endothelial cells. The aim of our study was to assess existing evidence of associations between reduced expression of E-cadherin and prognosis of ovarian cancer with a discussion of potential approaches to exploiting any prognostic value for improved clinical management. Methods: We conducted a meta-analysis of 9 studies (n=915 patients) focusing on the correlation of reduced expression of E-cadherin with overall survival. Data were synthesized with random or fixed effect hazard ratios. Results: The studies were categorized by author/year, number of patients, FIGO stage, histology, cutoff value for E-cadherin positivity, and methods of hazard rations (HR) estimation, HR and its 95% confidence interval (CI). Combined hazard ratios suggested that reduced expression of E-cadherin positivity was associated with poor overall survival (OS), HR= 2.10, 95% CI:1.13-3.06. Conclusion: The overall survival of the E-cadherin negative group with ovarian cancer was significant poorer than the E-cadherin positive group. Upregulation of E-cadherin is an attractive therapeutic approach that could exert significant effects on clinical outcome of ovarian cancer.
Keywords
E-cadherin; overall survival; ovarian cancer; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Altundag K, Altundag O, Akyurek S, et al (2006). Inactivation of E-cadherin and less sensitivity of lobular breast carcinoma cells to chemotherapy. Breast, 15, 300.   DOI
2 Barraclough H, Simms L, Govindan R (2011). Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol, 6, 978-2.   DOI
3 Berx G, van Roy F (2009). Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol, 1, a003129.   DOI
4 Blechschmidt K, Sassen S, Schmalfeldt B, et al (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer, 98, 489-5.   DOI
5 Carter JS, Downs LS Jr (2011). Ovarian cancer test and treatment. Female Patient (Parsippany). 36, 30-5.
6 Cho EY, Choi Y, Chae SW, et al (2006). Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int, 56, 62-0.   DOI
7 Cisco RM, Ford JM, Norton JA (2008). Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer, 113, 1850-6.   DOI
8 Darai E, Scoazec JY, Walker-Combrouze F, et al (1997). Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol, 28, 922-8.   DOI   ScienceOn
9 Dian D, Brüning A, Mylonas I (2011). E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis. Arch Gynecol Obstet, 284, 437-3.   DOI
10 Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 9, 550-62.   DOI
11 Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al (2004). Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Onco, 15, 1535-2.   DOI   ScienceOn
12 Fluge O, Bruland O, Akslen LA, et al (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid, 16, 161-5.   DOI
13 Ho CM, Cheng WF, Lin MC, et al (2010). Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer, 20, 1490-7.
14 Gadducci A, Ferdeghini M, Cosio S, et al (1999). Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res, 19, 769-2.
15 Haslehurst AM, Koti M, Dharsee M, et al (2012). EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 12, 91.   DOI   ScienceOn
16 Hirohashi S, Kanai Y (2003). Cell adhesion system and human cancer morphogenesis. Cancer Sci, 94, 575-1.   DOI   ScienceOn
17 Huang KJ, Sui LH (2012). The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol, 29, 318-3.   DOI
18 Janda E, Nevolo M, Lehmann K, et al (2006). Raf plus TGF betadependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene, 25, 7117-30.   DOI
19 Lau MT, Klausen C, Leung PC (2011). E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via $\beta$-catenin-Egr1-mediated PTEN expression. Oncogene, 30, 2753-66.   DOI   ScienceOn
20 Mareel M, Berx G, Van Roy F, et al (1996). Cadherin/catenin complex: a target for antiinvasive therapy? J Cell Biochem, 61, 524-0.   DOI
21 Martin B, Paesmans M, Mascaux C (2004).Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-5.   DOI   ScienceOn
22 Polyak K, Weinberg RA (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 9, 265-3.   DOI
23 Oza AM, Castonguay V, Tsoref D, et al (2011). Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol, Suppl 2: S20-7.
24 Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-4.   DOI
25 Perl AK, Wilgenbus P, Dahl U, et al (1998). A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 392, 190-3.   DOI   ScienceOn
26 Sawada K, Mitra AK, Radjabi AR, et al (2008). Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res, 68, 2329-39.   DOI
27 Shim HS, Yoon BS, Cho NH (2009). Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol, 40, 693-8.   DOI
28 St Croix B, Sheehan C, Rak JW, et al (1998). E-Cadherindependent growth suppression is mediated by the cyclindependent kinase inhibitor p27(KIP1). J Cell Biol, 142, 557-71.   DOI   ScienceOn
29 Vincan E, Barker N (2008). The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis, 25, 657-3.   DOI
30 Voutilainen KA, Anttila MA, Sillanpää SM, et al (2006). Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol, 59, 460-7.   DOI
31 Yu F, Yao H, Zhu P, et al (2007). Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-23.   DOI   ScienceOn
32 Yamamoto S, Tsuda H, Honda K, et al (2007). Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol, 20, 1278-5.   DOI
33 Yoshida J, Horiuchi A, Kikuchi N, et al (2009). Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma. Med Mol Morphol, 42, 82-1.   DOI
34 Yuecheng Y, Hongmei L, Xiaoyan X (2006). Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis, 23, 65-4.   DOI